Morocco sign two additional agreements for sufficient supply of COVID-19 Vaccine
London, Sep. 26, 2020 (AltAfrica)-Morocco has signed another two international agreements to secure sufficient anti-COVID-19 vaccines as soon as clinical trials are completed.
Head of Government, Saad Eddine El Othmani who announced the additional agreements said the the North African country had to do so because ” there is strong international competition to find an effective vaccine”
The official said the agreements was between his country and two Chinese and British-Swedish laboratory to secure anti-COVD-19 vaccines as soon as clinical trials are completed.
In a press briefing following the government council, Spokesperson of Government Saaid Amzazi said that the “world is living under the impact of the COVID-19 pandemic.”
Morocco’s government recently announced several agreements with international laboratories amid the rapid increase in COVID-19 cases and deaths.
On September 18, Minister of Health Khalid Ait Taleb signed a memorandum of understanding (MoU) to purchase doses of a COVID-19 vaccine from Russian pharmaceutical group R-Pharm.
The agreement aims to provide Morocco with sufficient supply of COVID-19 vaccines.
In August, Morocco put pen to paper with China National Biotec Group Limited (CNBG) on COVID-19 vaccine trials.
The country has to date reported 110,099 COVID-19 confirmed cases, including 90,186 recoveries, and 1,956 deaths.
One of the vaccine candidates, Novavax has become the eleventh Covid-19 vaccine candidate to reach the Phase 3 stage globally.
The vaccine in question is called NVX-CoV2373, a stable, prefusion protein made from the genetic sequence of SARS-CoV-2 — the virus that causes COVID-19 — with nanoparticle technology
It has shown some success in preclinical trials, demonstrating the ability to bind with receptors targeted by the virus. Those results showed high immunogenicity and high levels of neutralizing antibodies, meaning the candidate could be highly protective for humans.